Form 4: KalVista Director Fairey Receives 30,000 Stock Options

KalVista Pharmaceuticals, Inc. Director William Fairey was granted 30,000 stock options with an exercise price of $12.05, vesting over 12 months.

Summary

• William Fairey, a Director of KalVista Pharmaceuticals, Inc. (KALV), was granted 30,000 stock options.
• The options have an exercise price of $12.05 per share.
• The transaction date for the grant was October 1, 2025.
• The options will vest over a 12-month period, with 1/12th vesting on November 1, 2025, and subsequent 1/12th portions vesting monthly thereafter.
• Vesting is contingent upon Fairey's continued service to the company.
• The options expire on September 30, 2035.
• Following this transaction, Fairey beneficially owns 30,000 derivative securities directly.

Sentiment

Score: 6

Explanation: The grant of stock options to a director is generally a neutral to slightly positive event, as it aligns management's interests with shareholders. It's not a direct indicator of financial performance but rather a compensation and incentive mechanism.

Positives

• Aligns the interests of Director William Fairey with those of shareholders, as the options gain value only if the stock price increases above the exercise price.
• Provides a long-term incentive for the director to contribute to the company's growth and success, given the 10-year expiration date.

Negatives

• Potential for future dilution if the options are exercised, increasing the number of outstanding shares.
• The value of the options is entirely dependent on the future performance of KalVista's stock, introducing risk for the director.

Risks

• Market Price Volatility: The value of the stock options is directly tied to KalVista's common stock price, which can fluctuate significantly. If the stock price does not exceed the $12.05 exercise price, the options may expire worthless.
• Service Condition: Vesting of the options is subject to William Fairey's continued service to KalVista Pharmaceuticals, Inc.
• Dilution Risk: Upon exercise, these options will convert into common stock, potentially diluting the ownership percentage of existing shareholders.

Future Outlook

The grant of stock options with a future vesting schedule implies an expectation of continued service from the director and a long-term view on the company's potential for stock price appreciation, which would make the options valuable.

Industry Context

The granting of stock options is a common practice in the biotechnology and pharmaceutical industries to attract, retain, and incentivize key personnel, including directors, by aligning their financial interests with the long-term performance of the company's stock. This practice is particularly prevalent in growth-oriented sectors where future value creation is a primary focus.

Stakeholder Impact

• Shareholders: Potential for future dilution if options are exercised; improved alignment of director's interests with shareholder value creation.
• Director (William Fairey): Receives a significant long-term incentive tied to the company's stock performance.

Next Steps

• Continued service of William Fairey to KalVista Pharmaceuticals, Inc. to ensure vesting of options.
• Monthly vesting of 1/12th of the options starting November 1, 2025.

Key Dates

Keywords

KalVista Pharmaceuticals, KALV, William Fairey, Form 4, Insider Transaction, Stock Options, Director Compensation, Equity Grant, Vesting Schedule